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ABSTRACT
Introduction: No head-to-head trials have
compared the efficacy of the oral therapies,
fingolimod, dimethyl fumarate and
teriflunomide, in multiple sclerosis. Statistical
modeling approaches, which control for
differences in patient characteristics, can
improve indirect comparisons of the efficacy
of these therapies.
Methods: No evidence of disease activity
(NEDA) was evaluated as the proportion of
patients free from relapses and 3-month
confirmed disability progression (clinical
composite), free from gadolinium-enhancing
T1 lesions and new or newly enlarged T2
lesions (magnetic resonance imaging
composite), or free from all disease measures
(overall composite). For each measure, the
efficacy of fingolimod was estimated by
analyzing individual patient data from
fingolimod phase 3 trials using methodologies
from studies of other oral therapies. These data
were then used to build binomial regression
models, which adjusted for differences in
baseline characteristics between the studies.
Models predicted the indirect relative risk of
achieving NEDA status for fingolimod versus
dimethyl fumarate or teriflunomide in an
average patient from their respective phase 3
trials.
Results: The estimated relative risks of
achieving NEDA status for fingolimod versus
placebo in a pooled fingolimod trial population
were numerically greater (i.e., fingolimod more
efficacious) than the estimated relative risks for
dimethyl fumarate or teriflunomide versus
placebo in each respective trial population. In
indirect comparisons, the predicted relative
risks for all composite measures were better for
fingolimod than comparator when tested
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against the trial populations of those
treated with dimethyl fumarate (relative
risk, clinical: 1.21 [95% confidence interval
1.06–1.39]; overall: 1.67 [1.08–2.57]), teriflunomide
7 mg (clinical: 1.22 [1.02–1.46]; overall:
2.01 [1.38–2.93]) and teriflunomide
14 mg (clinical: 1.14 [0.96–1.36]; overall:
1.61 [1.12–2.31]).
Conclusion: Our modeling approach suggests
that fingolimod therapy results in a higher
probability of NEDA than dimethyl fumarate
and teriflunomide therapy when phase 3 trial
data are indirectly compared and differences
between trials are adjusted for.
Keywords: Disease-modifying therapies;
Fingolimod; Indirect comparison; Multiple
sclerosis; Neurology; Oral therapies
INTRODUCTION
Multiple sclerosis (MS) is a chronic,
neurodegenerative disease in which putative
auto-inflammatory responses attack myelinated
axons of the central nervous system (CNS),
causing the formation of scar tissue and
disruption of nerve impulses traveling to and
from the brain. This damage can result in a wide
range of possible physical and mental
symptoms [1]. Relapsing–remitting MS (RRMS),
the type of MS that is the first diagnosis in
80–85% of patients, is characterized by episodes
of neurological dysfunction, known as relapses,
followed by periods of remission. Disease-
modifying therapies (DMTs) form the
mainstay of first-line treatment for RRMS.
Until recently, most approved DMTs required
administration by injection (interferon beta and
glatiramer acetate) or intravenous infusion
(natalizumab). Injectable agents are, however,
associated with injection site reactions, as well
as other tolerability issues (such as influenza-
like symptoms), poor patient adherence and
moderate efficacy [2, 3]. Three new oral
therapies with different mechanisms of action
have recently been approved for the treatment
of MS. Fingolimod was the first oral therapy
approved for the treatment of relapsing MS. It
was approved as a first-line treatment in the
USA in September 2010, and was recommended
in the EU in March 2011 for the treatment of
patients with high disease activity despite
previous treatment with at least one other
DMT and individuals with rapidly evolving
severe RRMS [4]. Subsequently, teriflunomide
was approved in the USA in September 2012
and in Europe in March 2013 [5, 6]. Dimethyl
fumarate (DMF; BG-12) was approved in the
USA in March 2013 and recently in Europe as
well [7, 8].
DMTs aim to reduce the frequency and
severity of relapses, extend the time intervals
between relapses and slow progression to
permanent disability [2]. To assess these
treatment goals, annualized relapse rates
(ARRs) or time to first relapse and disability
progression, as measured by the expanded
disability status scale (EDSS), are the primary
clinical endpoints of phase 3 studies of
therapies for RRMS, with magnetic resonance
imaging (MRI) measures of disease activity and
burden (CNS lesions) as secondary endpoints.
Oral therapies have been shown to offer benefits
with regard to these clinical and MRI outcomes
when compared with placebo in phase 3 trials
[9–13]. The clinical efficacy of these therapies
over traditional injectable DMTs has been
demonstrated for fingolimod in the trial
assessing injectable interferon versus FTY720
oral in RRMS (TRANSFORMS) [14], and for the
7 mg dose (but not the 14 mg dose) of
teriflunomide in the teriflunomide and Rebif
(TENERE) trial [15]. Findings of these phase 3
trials indicate that most doses of oral therapies
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may represent an advance in the treatment of
MS because they offer effective treatment
options that are often better tolerated and
more convenient than the traditional
injectable DMTs.
In response to this therapeutic progress,
treatment expectations and goals have evolved
to encompass potential remission from the
progressive symptoms of MS, known as
freedom from disease activity or no evidence
of disease activity (NEDA) [16]. Several
exploratory analyses have investigated the
efficacy of oral DMTs versus placebo on
achieving NEDA status, defined as an absence
of relapses, disability progression lasting at
least 3 months and no new MRI lesions
[17–22]. Post hoc analyses of the 2-year,
placebo-controlled, phase 3 FTY720 research
evaluating effects of daily oral therapy in
multiple sclerosis (FREEDOMS) trial
demonstrated that a significantly higher
proportion of patients treated with
fingolimod 0.5 mg achieved NEDA status
than those treated with placebo (33% vs.
13%; P\0.001) [21]. In an integrated post
hoc analysis of the phase 3 determination of
the efficacy and safety of oral fumarate in
relapsing–remitting multiple sclerosis (DEFINE)
and comparator and an oral fumarate in
relapsing–remitting multiple sclerosis
(CONFIRM) trials, the proportion of
individuals free from disease activity over
2 years was higher for the DMF 240 mg twice
daily group than for the placebo group
(23% vs. 11%; P\0.0001) [20]. In a post hoc
analysis of teriflunomide multiple sclerosis
oral (TEMSO), a greater proportion of
patients treated with teriflunomide 7 or 14 mg
were free from disease activity than individuals
receiving placebo (18% and 23% vs. 14%;
P = 0.0293 and P = 0.0002, respectively) [23].
There are no head-to-head controlled trials
comparing the efficacy of the different oral
DMTs. This is an area of much interest to
neurologists and healthcare decision makers;
therefore, several indirect treatment
comparisons have recently been performed. Of
these, two studies have compared fingolimod
with teriflunomide [24, 25]. A network meta-
analysis (NMA) found a significantly lower ARR
with fingolimod than with teriflunomide
14 mg, but no significant difference in the
proportion of patients with 3-month
confirmed disability progression [24]. A
separate NMA study found no statistically
significant differences between fingolimod and
teriflunomide 7 or 14 mg on measures of
freedom from relapse and disease progression
[25]. A recent study has additionally compared
fingolimod with DMF using an NMA approach
and found no significant differences in ARR or
in the proportion of patients with disability
progression lasting at least 3 months [26].
Standard NMA methods may be susceptible
to bias because of differences in trial
populations and methodologies. The placebo-
controlled trials of these oral MS therapies are
not sufficiently similar and differences between
the trials, including differences in patient
populations, endpoint definitions and
methods for dealing with non-completers,
have not been taken into account in any of
the NMAs of these therapies performed to date.
Subgroup and post hoc analyses of the phase 3
trials of DMTs have demonstrated that
differences in patient baseline characteristics
influence the observed effect of DMTs on ARRs
and disability progression [14, 27], and that the
application of different definitions of disability
progression has a large impact on disability
outcomes [28]. Therefore, it is important to
adjust for these potentially confounding factors
when assessing the comparative efficacy of
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these oral DMTs. Limited methodology exists to
perform this type of adjusted comparison.
Therefore, we developed a statistical modeling
approach to compare treatment effects that
adjusted for differences in patient
characteristics and methodologies across the
MS trials and allowed for the use of a
combination of individual patient- and
population-level data, thus permitting the
utilization of all available data for these
treatments [29–32]. Here, we have compared
the effectiveness of oral therapies for MS
(fingolimod 0.5 mg, DMF 240 mg twice daily
and teriflunomide 7 or 14 mg) for achieving
NEDA status. Our modeling approach uses all
publicly available data for oral therapies and
individual patient-level data from the phase 3
placebo-controlled trials of fingolimod.
METHODS
Clinical Trials
The methodological details of the five double-
blind, randomized, controlled, phase 3 trials for
fingolimod (FREEDOMS and FREEDOMS II),
DMF (DEFINE and CONFIRM) and
teriflunomide (TEMSO) are described elsewhere
[9–13]. This analysis used data for the placebo
groups of these trials and the following
treatment groups: fingolimod 0.5 mg, DMF
240 mg twice daily and teriflunomide 7 and
14 mg. Comparisons with DMF 240 mg three
times daily were also performed. The number of
patients randomized to each group and the
differences in inclusion and exclusion criteria
among trials are described in Supplementary
Material S1. As data for this study were obtained
from these trials and do not involve any new
studies of human or animal subjects, ethical
approval or participant’s informed consent was
not required. All studies assessed ARR or time to
first relapse as the primary endpoint and time to
3-month confirmed disability progression as a
key secondary endpoint. Definitions of
3-month confirmed disability progression
differed across the trials. In FREEDOMS,
FREEDOMS II and TEMSO, confirmed
disability progression was considered to be an
increase of 1 EDSS point for patients with a
baseline score of 0–5.0, and of 0.5 points for
individuals with a baseline EDSS score of 5.5
(FREEDOMS) or greater than 5.5 (TEMSO). In
DEFINE and CONFIRM, confirmed disability
progression was defined as an increase of 1
point in individuals with an EDSS score of
1.0–5.0, and of at least 1.5 points in patients
with a baseline EDSS score of 0.
NEDA Outcomes
NEDA was evaluated as the proportion of
patients free from relapses, free from 3-month
confirmed disability progression, free from
gadolinium (Gd)-enhancing T1 lesions and
free from new or newly enlarged T2 lesions.
Using a similar methodology to the post hoc
analyses of the placebo-controlled, phase 3 trial
of natalizumab, AFFIRM [19], these individual
components were combined to assess NEDA in
three composite measures. The clinical
composite of NEDA measured freedom from
relapses and 3-month confirmed disability
progression. The MRI composite of NEDA
measured freedom from Gd-enhancing T1
lesions and new or newly enlarged T2 lesions.
The overall composite or overall NEDA
measured freedom from all of these disease
outcomes.
In the FREEDOMS trials, if patients did not
complete the trial and were disease free at
their last study visit, they were counted as
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having achieved NEDA status [21]. This
method was also assumed for the TEMSO
trial where all patients who were randomized
were included in the analysis, so we assumed
that a disease-free non-completer was counted
as having achieved NEDA status. In the
DEFINE and CONFIRM trials, it was assumed
that non-completers were removed from the
analysis if they were disease free because these
analyses were performed by the same
investigators as the original AFFIRM analyses,
which excluded these patients from analyses
[21]. In the absence of published information
from the DEFINE, CONFIRM and TEMSO trials
it was assumed that all patient visits (i.e., both
scheduled and unscheduled) were assessed for
presence of disease activity.
Statistical Modeling
Models were built to estimate the efficacy of
fingolimod in improving the probability (and
thereby relative risk [RR] compared with
placebo) of achieving NEDA status, and to
compare the efficacy with that of other DMTs.
Individual patient data from the pooled
fingolimod phase 3 trials, FREEDOMS and
FREEDOMS II, were used to build binomial
regression models to estimate the proportion
of patients achieving NEDA status. Data from
FREEDOMS and FREEDOMS II were pooled by
including a study-level stratifying variable. For
each component and composite measure, the
efficacy of fingolimod was estimated by re-
analyzing the individual patient data from the
fingolimod phase 3 trials using methodologies
from studies of other oral therapies (adjusted
only for endpoint definitions and how trial
non-completers contributed to the analyses).
Owing to differences in definitions and
methodologies between the trials, two slightly
different sets of models, termed ‘estimated’
models, were constructed; one for fingolimod
versus DMF and another for fingolimod versus
teriflunomide. Models for the DMF comparisons
were based on the same definitions of disability
progression used in the DEFINE and CONFIRM
trials for patients with an EDSS score of 0 at
baseline (i.e., 1.5-point change), whereas
models for teriflunomide comparisons utilized
the same definition as originally used in the
FREEDOMS study for patients with an EDSS
score of 0 at baseline (i.e., 1-point change). The
outcomes in the models also took into account
differences in the methods of dealing with non-
completers across the various trials, with
disease-free patients in FREEDOMS excluded
from the models for the DMF comparisons if
they did not complete the trial (as assumed in
the DEFINE and CONFIRM trials). Thus, these
estimates took into account methodological
differences between trials and were termed the
‘estimated’ RRs of achieving NEDA status. The
RR of achieving NEDA status for fingolimod
versus placebo and for DMF or teriflunomide
versus placebo was combined using the method
proposed by Bucher et al. [33] to assess the RR of
achieving NEDA status for fingolimod versus
DMF or teriflunomide. The need for different
adjustments to compare fingolimod with DMF
and teriflunomide prevented the use of an NMA
approach [34], and separate indirect
comparisons are needed to indirectly compare
the estimated RRs of achieving NEDA status for
fingolimod versus DMF and teriflunomide.
Because application of the indirect
comparison method proposed by Bucher et al.
[33] to the treatment effect estimates requires
the assumption that patient characteristics do
not influence the treatment effect, we extended
the method by building further models, based
on the estimated models, to adjust for possible
differences in baseline characteristics between
the studies. In each set of estimated models,
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which accounted for differences in
methodologies across trials, two models were
constructed for each component and composite
measure; an initial and a final model, in which
individual patient data from the FREEDOMS
trials were used to estimate the contribution of
baseline characteristics to measures of NEDA.
The prediction method for these initial and
final models is described in Supplementary
Material S2. Initial models were built by
including pre-specified baseline covariates as
main and treatment interaction (i.e., potential
treatment modifier) effects. Covariates likely to
modify the treatment effect were selected based
on the results of previous subgroup analyses of
FREEDOMS [35] and AFFIRM [36], as well as
clinical expert opinion. Final models were
developed by selecting the baseline covariates
that were most predictive of the respective
outcomes using a backward stepwise algorithm
that used the Akaike information criterion (AIC)
as the metric to retain the best, but simplest,
model. This method avoids over-parameterizing
the model. Goodness-of-fit was assessed by a
Hosmer–Lemeshow grouping method
(Supplementary Material S3). Initial models for
the DMF comparisons included the following
eight pre-specified baseline covariates
(continuous variables were centered about
their means): age, sex, previous DMT use,
duration of MS, number of relapses in the past
year, EDSS score at baseline (0–1.5, 2–2.5, C3),
number of Gd-enhancing T1 lesions and cube
root of the total volume of T2 lesions. Owing to
unavailability of data, the initial models for the
teriflunomide comparisons excluded the cube
root of total volume of T2 lesions. The EDSS
score was split into two categories (B3.5 and
[3.5) based on the stratification of randomized
patients in the TEMSO trial.
An indirect comparison of the oral therapies
was performed in three steps (Fig. 1). First,
models were used to predict the RR of
achieving NEDA status for fingolimod versus
placebo in an average patient in a pooled
DEFINE and CONFIRM population, and in the
TEMSO population (termed ‘predicted’ models
and ‘predicted’ RRs, respectively). Second, the
estimated RR of achieving NEDA status for
DMF versus placebo in the pooled DEFINE and
CONFIRM population was calculated using a
fixed-effect inverse variance-weighted method
of the RRs from each study, a standard method
for pooling outcomes from studies that
provides a weighted average of estimates. The
RRs from each study were found from data in
Havrdova et al. [20] reporting the probabilities
of patients achieving NEDA status in each arm,
with the variance of these probabilities
calculated from the sample size in each arm,
excluding disease-free patients who did not
complete the study. Because this number is not
reported, we estimated it assuming that non-
completers had the same likelihood of being
disease free as those who completed the trial.
This is likely to be a conservative assumption;
in the FREEDOMS study, non-completers were
less likely to be disease free than completers,
leading to the sample size being reduced too
much and an inflated variance of the pooled
RR estimate. Similar calculations for estimating
the RR of achieving NEDA status were
performed for teriflunomide versus placebo in
the TEMSO population using results from
Freedman et al. [23]. Third, the estimated RR
of achieving NEDA status for fingolimod versus
placebo in the pooled FREEDOMS population
(from the ‘estimated’ models) and the
predicted RRs for fingolimod versus placebo
in comparator trial populations (from the
‘predicted’ models) were compared with those
calculated for DMF and teriflunomide in their
respective trials. An indirect comparison of the
efficacy of fingolimod and DMF or
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teriflunomide was performed by comparing the
estimated RRs of achieving NEDA status for
each treatment versus placebo using the
Bucher et al. [33] method. Results are
expressed as the RR (95% confidence interval
[CI]) of achieving NEDA status, with an RR
greater than 1.0 indicating an improved
outcome; the higher the RR, the better the
outcome for the patient.
Compliance With Ethics Guidelines
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or




Patient baseline demographics and disease
characteristics in the pooled FREEDOMS and
FREEDOMS II, pooled DEFINE and CONFIRM,
and TEMSO populations are compared in
Table 1. In general, patient demographics and
the mean number of relapses in the past year
were similar across the trials, but there were
notable differences between the populations
regarding previous DMT use, the number of
Gd-enhancing lesions and the mean volume of
T2 lesions. In particular, more patients in the
pooled FREEDOMS population had previously







Estimated RRs of oral 
therapy versus placebo in 
respective phase 3 trial
Indirect RR of fingolimod 
versus placebo in  
comparator trial population
Predicted RR of
fingolimod versus placebo 






in the final model
Covariates included




using methodology from 
comparator trials
Fig. 1 Schematic of the modeling approach. aFinal models
selected baseline characteristics that were most predictive of
the outcome using a stepwise algorithm that used the
Akaike information criterion as the metric to retain the
best model. FREEDOMS FTY720 research evaluating
effects of daily oral therapy in multiple sclerosis, RR
relative risk
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Table 1 Baseline demographics and disease characteristics for patients in FREEDOMS and FREEDOMS II, DEFINE and
CONFIRM, and TEMSO
Characteristics FREEDOMS and FREEDOMS IIa
[9, 10] (N5 1,556)
DEFINE and CONFIRMb




Mean age, years 38.6 38.0 37.9
Sex, % female 74.3 71.9 72.2




Mean disease duration, years 9.2 8.1 [42] 8.7




0 7.9 5.1 NA
1.0–1.5 24.2 24.6 NA
2.0–2.5 31.9 29.3 NA
3.0–3.5 19.6 24.7 77.1c [43]
4.0–4.5 11.8 12.8 22.9d [43]
C5 4.7 3.6 NA




1.4 1.9 [11, 44] 1.7
Mean volume of T2-
weighted lesions, mm3
5,858 10,766 [44] NR
CONFIRM comparator and an oral fumarate in relapsing–remitting multiple sclerosis, DEFINE determination of the
efﬁcacy and safety of oral fumarate in relapsing–remitting multiple sclerosis, DMF dimethyl fumarate, DMT disease-
modifying therapy, EDSS expanded disability status scale, FREEDOMS FTY720 research evaluating effects of daily oral
therapy in multiple sclerosis, Gd gadolinium, MRI magnetic resonance imaging, NA not applicable, NR not reported,
TEMSO teriﬂunomide multiple sclerosis oral
a Fingolimod 0.5 mg and placebo groups only
b DMF twice daily, DMF three times daily and placebo groups
c Patients with EDSS score B3.5. The proportions of patients with EDSS scores of B3.5 are 83.6% in FREEDOMS and
FREEDOMS II, and 84.8% in DEFINE and CONFIRM
d Patients with EDSS score[3.5. The proportions of patients with EDSS scores of[3.5 are 16.4% in FREEDOMS and
FREEDOMS II, and 15.2% in DEFINE and CONFIRM
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Comparisons Without Adjustment
for Baseline Characteristics
When the efficacy of fingolimod was estimated
by analyzing patient data from the FREEDOMS
trials using methodologies from studies of other
oral therapies, the estimated RRs for fingolimod
versus placebo in the pooled FREEDOMS
population were consistently greater than the
estimated RRs for DMF versus placebo in the
pooled DEFINE and CONFIRM population, and
for teriflunomide versus placebo in TEMSO for
all composite measures of NEDA (Fig. 2). Using
the methodology in the DMF trials, the
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Fig. 2 RRs of achieving NEDA status for ﬁngolimod,
DMF and teriﬂunomide versus placebo. Estimated RRs for
the pooled FREEDOMS population, pooled DEFINE and
CONFIRM population, and TEMSO populations are
shown as solid lines as indicated (estimated). Dashed lines
represent the predicted RRs for ﬁngolimod versus placebo
in alternative trial populations using the ﬁnal models
(predicted). An RR above 1.0 indicates an improved
outcome for treatment relative to placebo. CONFIRM
comparator and an oral fumarate in relapsing–remitting
multiple sclerosis, DEFINE determination of the efﬁcacy
and safety of oral fumarate in relapsing–remitting multiple
sclerosis, DMF dimethyl fumarate, FREEDOMS FTY720
research evaluating effects of daily oral therapy in multiple
sclerosis, MRI magnetic resonance imaging, NEDA no
evidence of disease activity, RR relative risk, TEMSO
teriﬂunomide multiple sclerosis oral
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estimated RR (95% CI) of the overall composite,
or overall NEDA, for fingolimod versus placebo
in the pooled FREEDOMS population
(3.25 [2.51–4.21]) was greater than that for
DMF versus placebo in the pooled DEFINE and
CONFIRM population (2.05 [1.41–3.00]) (Fig. 2,
rows 1 and 2). Using the methodology in the
teriflunomide trials, the estimated RR of the
overall NEDA for fingolimod versus placebo in
the pooled FREEDOMS population
(2.78 [2.22–3.49]) was significantly greater
than that for teriflunomide 7 mg versus
placebo (1.28 [0.92–1.78]), and teriflunomide
14 mg versus placebo (1.59 [1.16–2.19]) in the
TEMSO population (Fig. 2, rows 4 and 5 for
7 mg dose and rows 4 and 6 for 14 mg dose).
Similar trends were seen for the clinical and MRI
composite measures (Fig. 2).
Baseline Covariates Selected for Inclusion
in the Final Models
The effect of each covariate included in the
initial models on the predicted clinical, MRI
and overall composite measures for fingolimod
versus placebo was explored by changing them
one at a time. To demonstrate the effect of
covariates on predicting the efficacy of
fingolimod, the clinical composite measure is
used as an example. In models for the DMF
comparisons, age and previous DMT use were
found to be the best predictors of no evidence of
clinical disease activity using AIC selection,
whereas age was found to be the only
predictor of no evidence of clinical disease
activity in the models for the teriflunomide
comparison. The covariates included in the
initial and final models for each component
measure are shown in Supplementary Material
S4 and Fig. 3, respectively.
Final Model Predictions
The covariates included in the final models can
predict the efficacy of fingolimod versus
placebo in an alternative trial population.
When the covariates that best predicted the
clinical composite measure, age and previous
DMT use, were included in the final models for
the DMF comparisons, the RR of showing NEDA
for the clinical composite for fingolimod versus
placebo was increased in younger or treatment-
naı¨ve patients (or decreased in older and
previously treated patients). As individuals in
the pooled DEFINE and CONFIRM population
were, on average, younger and more likely to be
treatment naı¨ve than in the pooled FREEDOMS
population, the model predicted a marginally
increased RR of achieving NEDA status for the
clinical composite in an average patient from
the pooled DEFINE and CONFIRM population
(RR: 1.58) than from the pooled FREEDOMS
population (RR: 1.54). For the final
teriflunomide model, which only included age
as a covariate because there was only a small
difference in age between the trial populations,
fingolimod was predicted to not perform
differently in the TEMSO population




Estimated RRs for fingolimod versus placebo in
the FREEDOMS trial populations were similar to
those predicted in the final models for
fingolimod versus placebo in a pooled
FREEDOMS population for all three composite
measures in both sets of analyses (data not
shown). This demonstrates the predictive ability
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of the model. Furthermore, the goodness-of-fit
assessed by Hosmer–Lemeshow grouping
showed that the predicted probabilities of
achieving NEDA status were consistent with
the reported data in the FREEDOMS trials (see
Supplementary Materials S3 and S5). The final
models were used to predict the efficacy of
fingolimod versus placebo in an average patient
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Fig. 3 Impact of baseline characteristics on predicted RRs
for ﬁngolimod versus placeboa (ﬁnal model). An RR above
1.0 indicates an improved outcome for treatment relative to
placebo. aFor non-categorical covariates, the model predicts
the treatment effect for setting that variable at the 1st and
3rd quartile of the distribution while holding all other
covariates constant. bVolume of T2 lesions at baseline was
not included in the initial model for the teriﬂunomide
analysis, and EDSS-deﬁned progression was reported
differently (0–3.5 instead of 0–1.5 in the DMF analysis).
BL baseline, DMF dimethyl fumarate, EDSS expanded
disability status scale, Gd gadolinium, MRI magnetic
resonance imaging, MS multiple sclerosis, NEDA no
evidence of disease activity, RR relative risk
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from the trial populations of DEFINE and
CONFIRM, and TEMSO. The predicted RRs for
fingolimod versus placebo in an average
individual from each of these trial populations
were marginally increased or similar to
estimated RRs for fingolimod in the pooled
FREEDOMS population for the three composite
measures of NEDA (Fig. 2, rows 1 and 3 for DMF
and rows 4 and 7 for teriflunomide). The only
exception was for the overall NEDA for the
teriflunomide comparison in that the predicted
RRs were slightly lower than estimates observed
for fingolimod (2.57 [2.16–3.06] for
teriflunomide versus 2.78 [2.22–3.49] for
fingolimod). The predicted RRs for fingolimod
versus placebo in the DEFINE and CONFIRM
population, and TEMSO population were
greater than those calculated for DMF and
teriflunomide, respectively, for all three
composite measures of NEDA (Fig. 2, rows 2
and 3 for DMF and rows 5, 6 and 7 for
teriflunomide).
RR of composite











FREEDOMS patient treated with
fingolimod (estimated) vs
DEFINE and CONFIRM patient treated
with DMF twice daily (estimated)
DEFINE and CONFIRM patient treated
with fingolimod (predicted) vs
DEFINE and CONFIRM patient treated
with DMF twice daily (estimated)
FREEDOMS patient treated with
fingolimod (estimated) vs
TEMSO patient treated with
teriflunomide 7 mg (estimated)
TEMSO patient treated with
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TEMSO patient treated with
teriflunomide 14 mg (estimated)
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Fig. 4 Indirect comparison of RRs of achieving NEDA
status for ﬁngolimod versus DMF or teriﬂunomide. An RR
above 1.0 indicates an improved outcome for ﬁngolimod
relative to comparator. Indirect comparisons were
performed using estimated RR for ﬁngolimod in a pooled
FREEDOMS and FREEDOMS II population (solid lines,
estimated) or using predicted RRs for ﬁngolimod in a
pooled DEFINE and CONFIRM or TEMSO population
(dashed line, predicted). CONFIRM comparator and an
oral fumarate in relapsing–remitting multiple sclerosis,
DEFINE determination of the efﬁcacy and safety of oral
fumarate in relapsing–remitting multiple sclerosis, DMF
dimethyl fumarate, FREEDOMS FTY720 research
evaluating effects of daily oral therapy in multiple sclerosis,
MRI magnetic resonance imaging, NEDA no evidence of
disease activity, RR relative risk, TEMSO teriﬂunomide
multiple sclerosis oral
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Indirect Comparison of Oral DMTs
for Measures of NEDA
In indirect comparisons, RRs were greater than
1 for fingolimod versus DMF or teriflunomide in
the DEFINE and CONFIRM, or TEMSO
populations, respectively. Similar results were
seen for the three composite measures of NEDA
with both estimated (Fig. 4, rows 1, 3 and 5) and
predicted values for fingolimod (Fig. 4, rows 2, 4
and 6). Indirect comparisons using predicted
RRs for fingolimod in an alternative trial
population were significantly greater than 1
for all analyses versus DMF in a pooled DEFINE
and CONFIRM population and for analyses
versus teriflunomide 7 and 14 mg in a TEMSO
population (with the exception of the clinical
composite for the teriflunomide 14 mg
comparison in which only a positive trend was
observed). For the overall NEDA, the indirect
comparison RRs for fingolimod in the trial
populations of DMF and teriflunomide were:
1.67 (1.08–2.57) versus DMF and 2.01
(1.38–2.93) and 1.61 (1.12–2.31) versus
teriflunomide 7 and 14 mg, respectively (Fig. 4,
rows 2, 4 and 6). Results for the individual
composite measures for the DMF comparisons
are presented in Supplementary Material S6;
data at this level are not available for
teriflunomide.
DISCUSSION
It is often useful for neurologists, health policy
makers and patients to compare the efficacy of
therapies for MS, and with the recent
introduction of these oral therapies, there is
much interest in their comparative
effectiveness. This study was a comparison of
the efficacy of oral DMTs using a statistical
modeling approach to account for differences
between the individual, placebo-controlled,
phase 3 trials conducted in patients with
RRMS. The approach estimated what the RRs
of achieving NEDA status would be between two
treatments using a comparison in the form A is
to B and C is to B to infer the comparison of A to
C. The results estimated that in comparisons
without covariate adjustment, the RR of
achieving NEDA status was higher for
fingolimod versus placebo than for DMF and
teriflunomide versus placebo, for the three
composite measures of NEDA. These results
remained similar when models adjusted for
differences between the phase 3 trial patient
populations. In addition, the indirect
comparisons of oral DMTs estimated that
fingolimod was more efficacious than both
DMF and teriflunomide (i.e., RRs [1) in their
respective trial populations for all three
composite measures of NEDA, and in most
cases these results were statistically significant.
Randomized head-to-head trials are the best
method for evaluating the efficacy of different
treatments. There is, however, a lack of head-to-
head clinical trials, so indirect comparisons
provide a means to assess the treatments. The
method proposed by Bucher et al. [33], in which
an indirect comparison of two therapies is
adjusted according to the results of their direct
comparisons with placebo, is valid only if
differences in the patient populations do not
affect the treatment effect and endpoints are
equally defined. Given that the FREEDOMS
trials were not sufficiently similar to the
DEFINE, CONFIRM and TEMSO trials, use of
the Bucher methodology without any
adaptation may not have provided a valid
comparison. In addition, we sought to use
individual patient-level data, which were
available for the FREEDOMS trials but not for
the DEFINE, CONFIRM and TEMSO trials. We
therefore developed a modeling approach for
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indirect comparisons, which was built upon the
Bucher method that adjusted for differences in
patient characteristics and methodologies
across the trials and allowed for the
combination of individual- and population-
level data to be used. The model was created
by expressing key outcomes from the pooled
FREEDOMS trials as a function of baseline
characteristics, and then applying this model
to an average patient in the pooled DEFINE and
CONFIRM trials, as well as to an average patient
in TEMSO, to predict the efficacy of fingolimod
versus placebo on three composite measures of
NEDA.
Table 2 Modeling methods for indirect treatment comparisons
Model Why it was not suitable for our analysis
Mixed treatment comparison using summary
level data
Does not take into account differences in patient population, endpoint
deﬁnitions and ways of dealing with non-completers between trials
and does not make use of individual patient-level data
Differences in patient populations could be accounted for using meta-
regression by including study-level treatment–covariate interactions
[45], but adjustments at the study level can be susceptible to the
ecological fallacy, where the relationship between outcome and
covariate may not be the same at the study and individual level
Differences in trial methodology could be accounted for using sub-
analyses but this requires a larger number of studies than is available
in the present case to enable estimation of the random effects
assuming that there is heterogeneity in treatment effect between
studies [46]
Mixed treatment comparison using individual
and summary level patient data [47]
Enables the use of individual patient data and adjustment for patient
populations, but it does not take into account differences in endpoint
deﬁnitions or the different ways of dealing with non-completers
This methodology can also be susceptible to ecological fallacy, require a
random effects model and a separate analysis to adjust for endpoint
deﬁnitions or the different ways of dealing with non-completers
Bucher pair-wise indirect comparison [33] Enables endpoint deﬁnitions or the different ways of dealing with non-
completers to be adjusted for, but does not make use of individual
patient data and adjust for patient populations
This methodology can be built on to adjust for patient characteristics
and use individual patient data as demonstrated in our study
Matching-adjusted indirect comparison [31] Enables the use of individual patient data, adjustment for patient
populations and trial methodology. This methodology uses individual
patient data from trials of one treatment to match baseline summary
statistics reported from trials of another treatment
This method adjusts for a predeﬁned set of patient baseline
characteristics and may over-ﬁt the prediction model. This approach
may not have sufﬁcient power for all treatments being assessed
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While alternate modeling approaches are
possible (see Table 2), these methods are less
suitable because they do not allow for all of the
following to be appropriately achieved: (1)
controlling for differences in patient
populations; (2) accounting for differences in
endpoint definitions; (3) accounting for the way
in which non-completers are dealt with; and (4)
using individual patient data where they are
available. For example, a Bayesian mixed
treatment comparison has been used to
compare the efficacy of teriflunomide with
other approved DMTs in the treatment of MS
[24]. Mixed treatment comparisons using
Poisson, mixed-log binomial, time-to-event
and continuous models have been used to
compare the efficacy and safety of DMF with
other approved DMTs including fingolimod.
However, these analyses could not adjust for
differences in trial methodology or endpoint
definitions across trials [26], and although this
could be achieved by performing sub-analyses,
these methods require data to be available from
several studies to enable reasonable estimation
of the random effects. Meta-analysis methods
are also available to synthesize individual
patient and aggregate data, and enable
adjustment for patient baseline characteristics
[37]. Such methods would also allow differences
in treatment effect due to differences in patient
population to be accounted for, using a
treatment–covariate interaction, but again
these methods would be hindered by not
having enough studies in the network to
enable reasonable estimation of the random
effects. The small number of studies and the
need to account for endpoint definitions by
performing additional sub-analyses (which
would reduce the number of studies even
further) made this method inappropriate in
our case. An alternate method that could have
been applied is the propensity score method of
Signorovitch et al. [31]. This method adjusts for
a predefined set of patient baseline
characteristics, whereas our approach selects
from such a set that best predicts the
treatment effect. In the case of MS, in which
studies have largely deduced potential
treatment modifiers, our approach avoids over-
parameterization of the model and enables
selection of a parsimonious model.
In this analysis, our modeling approach
suggests that differences in average patient
characteristics between the populations of the
clinical trials of the oral therapies have a
marginal impact on indirect comparisons of
NEDA outcomes, because model outputs before
adjustment for baseline covariates are similar to
the outputs after adjustment. Taking previous
DMT use as an example, the pooled FREEDOMS
population had a higher rate of previous DMT
use than the other trial populations. A smaller
effect on achieving NEDA status might
therefore be expected in this population than
in one with less previous DMT use, and this was
observed. Thus, adjusting for previous DMT use
is likely to improve the comparative
effectiveness of fingolimod relative to other
therapies studied in a population with lower
rates of DMT use. However, other differences in
trial populations might lead to a greater effect
on achieving NEDA status and the effects of
different variables may eventually cancel each
other out. Our methodology is indeed designed
to improve on simply comparing raw event
rates across studies. Our modeling approach
showed that differences in trial methodologies
had a greater impact on NEDA outcomes than
differences in patient characteristics, thus
highlighting the importance of adjusting for
these methodological differences. The impact of
these differences was exemplified by the RR
predicted when using the DEFINE and
CONFIRM approach of dealing with non-
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completers compared with using the TEMSO
method.
This study assessed treatment efficacy using
three composite measures of NEDA that were
based on the absence of relapses, disability
progression, Gd-enhancing T1 lesions, and
new or newly enlarged T2 lesions. These
individual component measures are well-
established indicators of disease activity and
are commonly assessed in clinical trials [17–22].
As the effectiveness of treatments for MS
increases, the composite endpoint of NEDA is
becoming an important measure for clinicians
and patients [16]. The use of these composite
endpoints, however, does have some
limitations because they do not take into
account other potentially important indicators
of disease activity, such as brain volume loss or
cognitive function. In addition, some analytical
adjustment to account for the dominance of
one component measure may potentially be
required. For example, one analysis has shown
that the overall composite endpoint is driven to
a large extent by MRI outcomes, with minimal
contribution from clinical measures [32].
Finally, the number and timing of MRI scans
were identical for the FREEDOMS trials and
DEFINE and CONFIRM, but different for
TEMSO. Imbalances in the timing or
scheduling of scans could have an impact on
MRI outcomes and the extent to which these
outcomes contribute to the overall NEDA.
Further research is needed to define the best
combination of criteria that represents NEDA in
MS and the best population in which to adjust
the results, but this study provides a valuable
exploration into the concepts.
Endpoint definitions also impact the results.
In an analysis of the CombiRx trial, which
evaluated interferon beta-1a and glatiramer
acetate in patients with RRMS, using a 1.0-
point increase in EDSS score as definition of
progression, 15% of individuals whose
screening EDSS score was greater than baseline
‘‘progressed’’ by month 3; that is, many went
back to their screening value leading to false
positive progressions and diminishing the
treatment effect. When a 1.5-point definition
of progression was used instead, the false
positive progressions were reduced, enhancing
the treatment effect [38]. A similar impact on
treatment effect was observed in the FREEDOMS
trials, where the treatment effect with respect to
3- and 6-month confirmed disability
progression was numerically greater when
requiring a 1.5-point change [28, 39]. Thus, in
our study, treatment effect may be lower in the
teriflunomide comparisons using the
FREEDOMS and TEMSO definition of disability
progression (1.0-point increase in patients with
a baseline EDSS score of 0), compared with the
DMF comparisons, which used the DEFINE and
CONFIRM definition (1.5-point increase in
patients with a baseline EDSS score of 0).
As with all statistical modeling, limitations
exist based on assumptions that are necessary to
make the modeling feasible. Firstly, indirect
treatment comparisons are a type of observation
research, owing to the non-randomized
selection of studies for inclusion in these
analyses, and are subject to confounding. Our
modeling approach, in contrast to several
alternative methodologies, reduces this
confounding by controlling for differences in
patient populations. In addition, our approach
is based on the Bucher method and is therefore
subject to the same assumptions as this
methodology, for example, the transitivity of
the treatment effects assumes we can learn
about the effect of A versus C via B [40].
Furthermore, it was assumed that the
outcomes of the trials were influenced by a
specific set of covariates, but it is possible and
indeed likely that results are affected by
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additional variables not included in the models,
such as the treatment environment at the time
these studies were conducted and/or the
countries or practices involved. We adjusted
for known baseline variables, but we could not
account for subtle unmeasured selection criteria
as sources of influence or bias. Controlled trials
in MS have demonstrated the relevance of such
hidden selection biases because identical
selection criteria have resulted in similar
baseline characteristics, but widely different
responses to placebo across studies [41]. In
addition, we had to make several assumptions
about the methodology used in the TEMSO
trial, because this information was not available
at the time of planning the analysis. We
assumed that the TEMSO trial used the same
method of dealing with non-completers as the
FREEDOMS trials, but it is possible that an
alternative method was used that should have
been controlled for in the models. There may
also have been additional differences in study
methodologies that could affect the results,
which we did not account for, such as
differences between trials in the use of
unscheduled visits for assessing suspected
relapses or disability progression. For example,
if unscheduled visits (in contrast to scheduled
visits) were used to confirm disability
progression, an impact on the overall
disability progression rate could occur. There is
also uncertainty regarding the standard
population chosen in which to adjust the
results. Statistical analyses usually assume that
all patients are at a similar risk of disease
activity, but if the adjusted covariate is a key
variable, the results could differ considerably in
different populations. We also assumed that
non-completers had the same likelihood of
being disease free as those who completed a
trial. This might have led the efficacy results of
two therapies to be more similar than in reality
if the less effective DMT was associated with
higher dropout rates but the number of
completers was similar to completers taking
the more effective therapy. Lastly, we assumed
that the probability of achieving NEDA status
could be reasonably predicted using a linear
model. The goodness-of-fit assessment
demonstrated that the predicted probability of
achieving NEDA status was similar to the
observed probability of achieving NEDA status,
suggesting that this was an appropriate choice
of model. Our conclusions must be interpreted
with caution because of the assumptions
inherent in any indirect comparison.
CONCLUSIONS
Our modeling approach, which controlled for
known or suspected treatment modifiers and
differences in patient characteristics between
the trials, predicted that those treated with
fingolimod in some comparisons have a
significantly higher probability of achieving
NEDA status compared with those treated with
DMF and teriflunomide for the three composite
measures in both unadjusted and adjusted
indirect comparisons. The statistical modeling
suggests that differences in patient
characteristics between the trials have a
marginal impact on indirect comparisons of
these treatments. In the absence of direct, head-
to-head comparisons, our modeling approach
can be used to make informed conclusions
about the comparative efficacy of oral DMTs
in patients with MS. These findings should,
however, be interpreted with caution, owing to
the assumptions inherent in any modeling
approach.
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